Gold compound

"Gold compound DMARD activity" is not a specific molecular target or receptor but rather refers to the class effect of gold-containing drugs used as disease-modifying antirheumatic drugs (DMARDs). These compounds—such as auranofin and sodium aurothiomalate—are small molecules that contain gold and are used primarily for the treatment of rheumatoid arthritis. Their therapeutic action is attributed to broad immunomodulatory effects including inhibition of monocyte/macrophage function, reduction in cytokine production, suppression of lymphocyte proliferation, decreased antibody formation, and interference with fibroblast/endothelial cell proliferation. The precise molecular targets remain incompletely defined; instead, these agents act on multiple cellular pathways involved in inflammation. Due to their non-specific mechanism and significant safety concerns—including nephrotoxicity and hematologic toxicity—the use of gold compounds has declined with the advent of more targeted therapies such as methotrexate or biologics. "Gold compound DMARD activity" should not be considered a canonical therapeutic target but rather describes a pharmacological property shared by this drug class[1][3][4][5][6]. **Note:** This entry is marked as incorrect because it does not refer to an individual molecule or receptor but rather describes an entire drug class's pharmacological effect. For structured data purposes, each specific gold-based DMARD should be mapped individually to its known protein targets where possible; otherwise this entry should be flagged for review.

Other names

Gold-containing drugGold saltChrysotherapyAurotherapyDisease-modifying antirheumatic gold compound

Modulation of immune system responses[4][7] Inhibition of prostaglandin synthesis[3] Reduction in cytokine expression by macrophages[4] Suppression of antibody production and proteolytic enzyme activity[4]